Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting

Segment reporting

6 Months Ended

Jan. 31, 2012

Segment Reporting Disclosure [Text Block]

Note 12 – Segment reporting

The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.

Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2012


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	14,123			—			—			—		$	14,123
Product revenues		—		$	9,542			—			—			9,542
Royalty and license fee income		—			1,308			—			—			1,308

		14,123			10,850			—			—			24,973

Operating expenses:
Cost of clinical laboratory services		8,709			—			—			—			8,709
Cost of product revenues		—			4,685			—			—			4,685
Research and development		71			1,136		$	496			—			1,703
Selling, general and administrative		5,190			4,227			—		$	2,070			11,487
Provision for uncollectible accounts receivable		1,146			23			—			—			1,169
Legal		69			118			—			836			1,023

Total operating expenses		15,185			10,189			496			2,906			28,776


Operating income (loss)		(1,062	)		661			(496	)		(2,906	)		(3,803	)

Other income (expense)
Interest		(1	)		15			—			—			14
Other		17			47			—			3			65
Foreign currency loss		—			(352	)		—			—			(352	)

Income (loss) before income taxes	$	(1,046	)	$	371		$	(496	)	$	(2,903	)	$	(4,076	)


Depreciation and amortization included above	$	269		$	734		$	11		$	31		$	1,045


Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	1			—			—			1
Selling, general and administrative		11			20			—		$	182			213

Total	$	14		$	21			—		$	182		$	217


Capital expenditures	$	241		$	62		$	—		$	—		$	303

Three months ended January 31, 2011


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	12,278			—			—			—		$	12,278
Product revenues		—		$	10,237			—			—			10,237
Royalty and license fee income		—			1,219			—			—			1,219

		12,278			11,456			—			—			23,734

Operating expenses:
Cost of clinical laboratory services		7,492			—			—			—			7,492
Cost of product revenues		—			5,911			—			—			5,911
Research and development		—			1,492		$	529			—			2,021
Selling, general and administrative		4,578			4,299			—		$	2,663			11,540
Provision for uncollectible accounts receivable		944			13			—			—			957
Legal		71			96			—			1,210			1,377

Total operating expenses		13,085			11,811			529			3,873			29,298


Operating income (loss)		(807	)		(355	)		(529	)		(3,873	)		(5,564	)

Other income (expense)
Interest		1			1			—			2			4
Other		7			—			—			55			62
Foreign currency loss		—			(64	)		—			—			(64	)

Income (loss) before income taxes	$	(799	)	$	(418	)	$	(529	)	$	(3,816	)	$	(5,562	)


Depreciation and amortization included above	$	243		$	811		$	12		$	33		$	1,099


Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	7			—			—			7
Selling, general and administrative		18			20			—		$	271			309

Total	$	21		$	27			—		$	271		$	319


Capital expenditures	$	248		$	83			—		$	—		$	331

The following financial information represents the operating results of the reportable segments of the Company:

Six months ended January 31, 2012


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated


Revenues:
Clinical laboratory services	$	28,310			—			—			—		$	28,310
Product revenues		—		$	19,245			—			—			19,245
Royalty and license fee income		—			3,170			—			—			3,170

		28,310			22,415			—			—			50,725


Operating expenses:
Cost of clinical laboratory services		17,523			—			—			—			17,523
Cost of product revenues		—			9,822			—			—			9,822
Research and development		115			2,184		$	1,029			—			3,328
Selling, general and administrative		10,020			9,455			—		$	4,397			23,872
Provision for uncollectible accounts receivable		2,419			36			—			—			2,455
Legal		112			502			—			1,278			1,892

Total operating expenses		30,189			21,999			1,029			5,675			58,892


Operating Income (loss)		(1,879	)		416			(1,029	)		(5,675	)		(8,167	)

Other income (expense)
Interest		(2	)		14			—			—			12
Other		22			41			—			10			76
Foreign currency loss		—			(323	)		—			—			(323	)

Income (loss) before income taxes	$	(1,859	)	$	148		$	(1,029	)	$	(5,665	)	$	(8,402	)


Depreciation and amortization included above	$	535		$	1,640		$	22		$	62		$	2,259


Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—			5
Research and development		—		$	4			—			—		$	4
Selling, general and administrative		27			40			—		$	354			421

Total	$	32		$	44			—		$	354		$	430


Capital expenditures	$	431		$	113		$	—		$	—		$	544

Six months ended January 31, 2011


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	24,668			—			—			—		$	24,668
Product revenues		—		$	20,421			—			—			20,421
Royalty and license fee income		—			4,297			—			—			4,297

		24,668			24,718			—			—			49,386

Operating expenses:
Cost of clinical laboratory services		15,065			—			—			—			15,065
Cost of product revenues		—			10,516			—			—			10,516
Research and development		—			2,757		$	1,021			—			3,778
Selling, general and administrative		9,098			8,547			—		$	4,927			22,572
Provision for uncollectible accounts receivable		2,025			7			—			—			2,032
Legal		161			195			—			1,717			2,073

Total operating expenses		26,349			22,022			1,021			6,644			56,036


Operating income (loss)		(1,681	)		2,696			(1,021	)		(6,644	)		(6,650	)

Other income (expense)
Interest		(3	)		(1	)		—			13			9
Other		10			3			—			63			76
Foreign currency loss		—			(56	)		—			—			(56	)

Income (loss) before income taxes	$	(1,674	)	$	2,642		$	(1,021	)	$	(6,568	)	$	(6,621	)


Depreciation and amortization included above	$	492		$	1,581		$	24		$	65		$	2,162


Share-based compensation included in above:
Cost of clinical laboratory services	$	6			—			—			—		$	6
Research and development		—		$	10			—			—			10
Selling, general and administrative		33			46			—		$	551			630

Total	$	39		$	56			—		$	551		$	646


Capital expenditures	$	377		$	196			—		$	—		$	573

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details